T Stamp Inc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that T Stamp Inc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $0 | Apr 7, 2022 |
| FY2021 | Dec 31, 2020 | $904.0K | Apr 7, 2022 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.14M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $3.08M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $4.56M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $5.39M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $3.68M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $2.65M | Apr 7, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.33M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($12.54M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($7.64M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($12.09M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($9.06M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($10.68M) | Apr 7, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.66M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($9.37M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($7.89M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($12.08M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($8.89M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($8.40M) | Apr 7, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.17M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $2.14M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $2.35M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $2.47M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $2.53M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $2.74M | Apr 7, 2022 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.47M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $8.51M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $8.40M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $12.44M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $8.31M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $6.38M | Apr 7, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.69M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($8.92M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($7.85M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($6.34M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($6.70M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($4.48M) | Apr 7, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $46.1K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $14.7K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $4.7K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $30.8K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $34.2K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $130.1K | Apr 7, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.24M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $8.60M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $7.89M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $6.41M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $8.66M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $4.81M | Apr 7, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.35M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $5.41M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $3.98M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $5.79M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $3.63M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $2.74M | Apr 7, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.73M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $3.03M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $3.75M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $463.7K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $4.87M | Mar 30, 2023 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.25M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.25M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $1.25M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.25M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.25M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $1.25M | Apr 7, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($69.78M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($61.46M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($50.85M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($39.30M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($27.21M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($18.15M) | Apr 7, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.04M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $2.78M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $3.14M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.25M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $3.48M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $1.47M | Apr 7, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (11) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (16) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Apr 7, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (11) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (16) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Apr 7, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 5.25M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 2.02M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 609,557 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 4.85M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 4.10M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 17.70M | Apr 7, 2022 |